Artificial Intelligence (AI) In Pharmaceutical Market Size (2024 - 2029)

The market size for artificial intelligence in the pharmaceutical industry is projected to experience significant growth during the forecast period. This expansion is driven by the increasing adoption of AI in clinical trials, cross-industry collaborations, and the need to reduce drug discovery and development costs and timelines. The efficiency of AI in accelerating the clinical trial process and therapeutic asset development is a key factor contributing to this growth. However, challenges such as a shortage of skilled professionals and incompatible healthcare IT infrastructure may impede the market's expansion.

Market Size of Artificial Intelligence (AI) In Pharmaceutical Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Artificial Intelligence (AI) In Pharmaceutical Market Summary
Study Period 2021 - 2029
Market Size (2024) USD 3.05 Billion
Market Size (2029) USD 18.06 Billion
CAGR (2024 - 2029) 42.68 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Artificial Intelligence (AI) In Pharmaceutical Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Artificial Intelligence (AI) In Pharmaceutical Market Analysis

The Artificial Intelligence In Pharmaceutical Market size is estimated at USD 3.05 billion in 2024, and is expected to reach USD 18.06 billion by 2029, growing at a CAGR of 42.68% during the forecast period (2024-2029).

Several factors are driving the growth of the AI pharmaceutical market during the forecast period. The increasing adoption of AI for clinical trials, a growing number of cross-industry collaborations and partnerships, and a rising need to reduce drug discovery and development costs and timelines are major drivers. Many companies are leveraging AI to speed up the clinical trial process and reduce completion time. For instance, in February 2022, Hong Kong-based company Insilico Medicine completed a Phase 0 clinical study and entered a Phase I clinical trial with its anti-fibrotic drug candidate for a novel target discovered using the company's artificial intelligence platform Pharma.ai.

The total time from the target discovery program initiation to the start of Phase I took less than 30 months, representing a new level in the speed of therapeutic asset development for the pharmaceutical industry. The accelerated timeline from target discovery to Phase I initiation highlights the efficiency of artificial intelligence in drug development, thereby driving its adoption and growth in the pharmaceutical market. For instance, in June 2023, Sanofi launched its new application, Plai, developed with artificial intelligence (AI) platform company Aily Labs. It delivers real-time, reactive data interactions and gives an unprecedented 360° view across all Sanofi activities.

Similarly, in December 2022, Cyclica Inc. and SK Chemicals Co. Ltd entered an artificial intelligence (AI)-driven drug discovery and development partnership to develop therapies across various disease areas. Under the collaboration with SK Chemicals, Cyclica will deploy its robust, proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to Cyclica and SK Chemicals.

Therefore, the adoption of AI as an asset to accelerate the healthcare process is expected to increase in the future, driving the growth of the market during the forecast period.

Despite the positive factors, the need for more skilled professionals and incompatible healthcare IT infrastructure in pharmaceutical research centers are expected to hinder the growth of the market during the forecast period.

Artificial Intelligence (AI) In Pharmaceutical Industry Segmentation

As per the scope of the report, AI in the pharmaceutical industry is used to handle data and present results that encourage better decision-making and save human effort, cost, and time. Artificial intelligence in the pharmaceutical industry is segmented by technology, type, application, and geography. The technology segment is further segmented into machine learning and other technologies. The type segment is further divided into software and services. The application segment is further bifurcated into drug discovery, clinical trials, laboratory automation, and others. Geography is divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Technology
Machine Learning
Other Technologies
By Type
Software
Services
By Application
Drug Discovery
Clinical Trial
Laboratory Automation
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Artificial Intelligence (AI) In Pharmaceutical Market Size Summary

The artificial intelligence in the pharmaceutical industry is experiencing rapid growth, driven by the increasing adoption of AI technologies to enhance clinical trials and streamline drug discovery processes. The market is characterized by significant investments and strategic collaborations among key players, aiming to reduce the time and cost associated with drug development. Companies are leveraging AI to accelerate clinical trials and improve the efficiency of therapeutic asset development, as evidenced by notable advancements such as Insilico Medicine's expedited clinical study timelines. The drug discovery segment is poised to capture a substantial market share, fueled by the rising prevalence of chronic and rare diseases and heightened research and development activities. Cross-industry partnerships, such as those between Cyclica Inc. and SK Chemicals Co. Ltd, are further expanding AI-driven drug development services, contributing to the market's robust growth trajectory.

North America is anticipated to witness significant expansion in the AI pharmaceutical market, supported by technological advancements and a growing number of drug discoveries. The region's market growth is bolstered by the presence of numerous industry players and strategic collaborations, such as the partnership between Insilico Medicine and EQRx. The establishment of new AI centers, like Sanofi's Artificial Intelligence Centre of Excellence in Toronto, is expected to enhance research and development activities, further propelling market growth. The competitive landscape remains fragmented, with major players like Alphabet Inc. (Isomorphic Labs), Atomwise Inc., and BenevolentAI striving to differentiate themselves in a crowded market. As the industry continues to evolve, the competitive rivalry is expected to remain high, driving innovation and expansion in the AI pharmaceutical sector.

Explore More

Artificial Intelligence (AI) In Pharmaceutical Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Number of Cross-industry Collaborations and Partnerships

      2. 1.2.2 Surge In Adoption of Artificial Intelligence (AI) for Clinical Trials

      3. 1.2.3 Increasing Need to Reduce Drug Discovery & Development Costs and Timelines

    3. 1.3 Market Restraints

      1. 1.3.1 Inadequate Availability of Skilled Professionals

      2. 1.3.2 Incompatible Healthcare IT Infrastructure

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Technology

      1. 2.1.1 Machine Learning

      2. 2.1.2 Other Technologies

    2. 2.2 By Type

      1. 2.2.1 Software

      2. 2.2.2 Services

    3. 2.3 By Application

      1. 2.3.1 Drug Discovery

      2. 2.3.2 Clinical Trial

      3. 2.3.3 Laboratory Automation

      4. 2.3.4 Other Applications

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Artificial Intelligence (AI) In Pharmaceutical Market Size FAQs

The Artificial Intelligence In Pharmaceutical Market size is expected to reach USD 3.05 billion in 2024 and grow at a CAGR of 42.68% to reach USD 18.06 billion by 2029.

In 2024, the Artificial Intelligence In Pharmaceutical Market size is expected to reach USD 3.05 billion.

Artificial Intelligence in Pharmaceutical Industry Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)